TLDR The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
The document discussed the CombAT study, a 4-year investigation comparing the effects of dutasteride (DUT) and tamsulosin (TAM), both individually and combined, on benign prostatic hyperplasia (BPH) symptoms and progression. It aimed to evaluate whether differences in inclusion criteria between CombAT and the previously completed MTOPS study, which examined doxazosin (DOX) and finasteride (FIN), led to a different patient group in CombAT. The analysis focused on comparing the inclusion criteria and baseline parameters of the two studies.
1 citations
,
June 2021 in “Singapore Medical Journal” Dutasteride and finasteride can help increase hair growth gene expression but need further improvement.
19 citations
,
April 2020 in “Dermatologic Therapy” Dutasteride works better than finasteride for hair loss, with both being safe to use.
January 2018 in “Surgical and Cosmetic Dermatology” 5-alpha reductase inhibitors like finasteride and dutasteride are effective for treating enlarged prostate and male pattern hair loss.
8 citations
,
January 2016 in “Indian Journal of Pharmacology” Finasteride and dutasteride can cause severe, lasting side effects.
47 citations
,
January 2003 in “Current opinion in urology” A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
